Nicolas Wisniacki

1PUBLICATIONS
7CO-AUTHORS
Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (1)

|Nov 04, 2020
A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.

Bart Keymeulen, André van Maurik, Dave Inman

Pageof 1

Frequent Collaborators

1 joint publications

Dave Inman

1 joint publications

João Oliveira

1 joint publications

Bart O Roep

1 joint publications

Pieter Gillard